anifrolumab sell brand name saphnelo monoclon antibodi use treatment system lupus erythematosus sle bind type interferon receptor block activ type interferon interferon interferonmed citat need anifrolumab approv medic use unit state august common advers effect shingl occur patient lowdos group highdos group placebo group overal advers effect rate compar group drug develop medimmun unit astrazeneca choos move anifrolumab instead sifalimumab phase iii trial lupus anifrolumab fail meet endpoint signific reduct diseas assess sle respond index instrument tulip phase iii trial multicent doubleblind placebocontroll studi follow adult moder sever sle cours one year preliminari result announc august citat need decemb committe medicin product human use chmp european medicin agenc ema adopt posit opinion recommend grant market author medicin product saphnelo intend treatment moder sever system lupus erythematosus sle applic medicin product astrazeneca ab anifrolumab intern nonproprietari name inn